Efficacy and safety of hyperthermic intraperitoneal chemotherapy in treatment of primary or recurrent ovarian cancer: systematic review and meta-analysis - Top-Institutions - MDSpire

Efficacy and safety of hyperthermic intraperitoneal chemotherapy in treatment of primary or recurrent ovarian cancer: systematic review and meta-analysis

  • By

  • Abdullah Ali Al Ameer

  • Shahad Essa Alrehaili

  • Doaa Wahib Nabulsy

  • Fatimah Osama Alhamdan

  • Lina Saleh Aljedani

  • Dareen Khalid Abdulshafi

  • Bedoor Obidallah Alghanmi

  • Abdulrahman Saleh Al-Mulhim

  • June 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    National Cancer Center
    National Cancer Center

    Goyang, South Korea

    Key Differentiators

    • Oncology

  • #4

    Ajou University Hospital
    Ajou University Hospital

    Suwon, South Korea

    Key Differentiators

    • Oncology

  • #5

    Regional Cancer Institute
    Regional Cancer Institute

    Montpelier, France

    Key Differentiators

    • Oncology

Original Source(s)

Efficacy and safety of hyperthermic intraperitoneal chemotherapy in treatment of primary or recurrent ovarian cancer: systematic review and meta-analysis

  • by Abdullah Ali Al Ameer, Shahad Essa Alrehaili, Doaa Wahib Nabulsy, Fatimah Osama Alhamdan, Lina Saleh Aljedani, Dareen Khalid Abdulshafi, Bedoor Obidallah Alghanmi, Abdulrahman Saleh Al-Mulhim

  • June 11, 2026

Related Content

Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches

Clinical outcomes of cancer patients with pre-existing autoimmune thyroid disease treated with PD-(L)-1 inhibitors: a propensity score methodology with inverse probability of treatment weighting retrospective study

Obesity-driven metabolic reprogramming and immune dysfunction in renal cancer